Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings

AI-generated analysis

📉 Evercore ISI analyst Vijay Kumar lowered Abbott's price target to $134 from $138 while maintaining an Outperform rating.

💼 BTIG also reduced its price goal for Abbott to $131 from $140 but kept a Buy recommendation.

🏥 The BTIG update incorporates the newly acquired Exact Sciences business into its valuation model.

💊 Tri.Fr trial data on Abbott's TriClip device was presented at the American College of Cardiology session, showing benefits for heart failure patients.

🏭 Abbott Laboratories operates as a global healthcare company across four main segments: Pharmaceuticals, Diagnostics, Nutrition, and Medical Devices.

📈 Both analyst firms maintain positive long-term outlooks despite lowering their specific price targets.

🔎 Evercore ISI provided this update as part of its broader Q1 preview for the medical technology and life sciences sector.

⚠️ A separate note from the article suggests some investors prefer AI stocks over Abbott due to perceived upside potential.

Bullish Signals
  • Abbott Laboratories (NYSE:ABT) is included among the 15 Best Consistent Dividend Stocks to Buy Right Now.
  • Evercore ISI analyst Vijay Kumar maintained an Outperform rating on Abbott shares despite lowering the price target.
  • BTIG maintained a Buy rating and updated its model to include the recently acquired Exact Sciences business, adding revenue synergies.
  • New data from the Tri.Fr trial presented at the American College of Cardiology Scientific Session showed a reduction in a composite outcome for the TriClip group, including first hospitalization for heart failure, tricuspid valve surgery, or cardiovascular death.
Risk Factors
  • Evercore ISI analyst Vijay Kumar lowered the firm's price recommendation on Abbott Laboratories (NYSE:ABT) from $138 to $134, reflecting downward pressure despite an Outperform rating.
  • BTIG reduced its price goal on Abbott from $140 to $131 following the recent acquisition of Exact Sciences, signaling concerns about integration or valuation adjustments related to this new business unit.
  • New data from the Tri.Fr trial regarding Abbott's TriClip device showed a reduction in primary outcomes for patients in the treatment group compared to control medical therapy, with strict exclusion criteria preventing cross-over that may complicate long-term efficacy assessments.
  • Analysts suggest that certain AI stocks offer greater upside potential and carry less downside risk than Abbott Laboratories, indicating relative weakness in the current investment thesis for ABT.
  • The company faces scrutiny over its four distinct segments—Established Pharmaceutical, Diagnostic, Nutritional, and Medical Devices—as growth drivers may be uneven across these categories following the Exact Sciences acquisition.
Full Analysis
Analyst Vijay Kumar at Evercore ISI lowered Abbott Laboratories (NYSE:ABT) price target to $134 from $138 on April 6, though the firm maintained an Outperform rating within its Q1 medical technology preview. Separately, BTIG reduced its price goal to $131 from $140 as of March 31 while sustaining a Buy rating, citing updated models that now incorporate Exact Sciences following its recent acquisition and new data from the Tri.Fr trial for the TriClip device. The Tri.Fr study results were presented at the American College of Cardiology Scientific Session, showing a reduction in composite outcomes—such as first hospitalization for heart failure, tricuspid valve surgery, or cardiovascular death—in the TriClip group compared to control patients who could not cross over to treatment. Abbott operates globally across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The content includes a generic market overview promoting AI stocks unrelated to Abbott and standard website footer text regarding newsletter sign-ups, portfolio access, and search tips. The core analysis focuses on the price target adjustments and specific business catalysts like the Exact Sciences integration and cardiac device trial data.